Breast Cancer AI Is Entering the Pathology Lab — and the Real-World Questions Are Getting Harder
Medical News Today highlights the tension between AI’s promise in melanoma and the realities of clinical deployment, while Devdiscourse points to AI-driven pathology reshaping breast cancer detection and prognosis. Together, they underscore a field moving from proof-of-concept toward questions of trust, integration, and accountability.
The most important shift in oncology AI may be happening in pathology rather than radiology. Unlike image triage tools that flag abnormalities, pathology systems are being asked to help determine diagnosis, prognosis, and sometimes treatment direction — a much heavier clinical responsibility.
That creates a new bar for evaluation. It is not enough for a model to be accurate on a test set; it must be explainable enough for pathologists to use, robust enough to handle tissue variability, and calibrated enough to avoid overconfidence in borderline cases. The stakes are especially high in breast cancer, where subtle differences can affect downstream decisions.
The melanoma coverage adds an important cautionary note: real-world use often exposes weaknesses that benchmark studies miss. Workflow fit, liability concerns, and the need for human confirmation can slow adoption even when the technology looks strong on paper.
What makes pathology attractive, though, is that it aligns with how oncology increasingly works: layered decisions supported by multiple data types. If AI can reliably surface patterns that pathologists already review, it could improve consistency and speed. But if it is positioned as a replacement for expert judgment, the gap between promise and practice will likely widen.